Boston Scientific upgraded by JMP to market perform

Boston Scientific Corp. was upgraded by JMP Securities analyst Robert C. Faulkner to market perform from market underperform after the company announced a bid to acquire Guidant. The deal cures most of JMP's issues with Boston Scientific, including lack of visibility on earnings, growth and threats to its stents business. Shares of the Natick, Mass., medical device company were down 98 cents, or 3.59%, at $26.35 on volume of 38,364,400 shares versus the three-month running average of 4,564,740 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.